The Florida Melanoma Trial I: A Prospective Multicenter Phase I/II Trial of Postoperative Hypofractionated Adjuvant Radiotherapy with Concurrent Interferon-Alfa-2b in the Treatment of Advanced Stage III Melanoma with Long-Term Toxicity Follow-Up
Table 1
Baseline characteristics ().
Sex
M
13 (56.5)
F
10 (43.5)
Race
White
22 (95.7)
Hispanic
1 (4.3)
Staging
Missing
4 (17.4)
1
1 (4.3)
2
5 (21.7)
3
7 (30.4)
5
6 (26.1)
Initial ECOG performance status (PS)
Missing
2 (8.7)
0
14 (60.9)
1
7 (30.4)
End of treatment ECOG PS
Missing
3 (13.0)
0
3 (13.0)
1
16 (69.6)
2
1 (4.3)
ECOG PS change (end versus baseline)
Missing
5 (21.7)
Better
1 (4.3)
Same
6 (26.1)
Worse
11 (47.8)
Number of eligibility items qualified*
1
12 (52.2)
2
9 (39.1)
3
2 (8.7)
Qualified for criterion (1)
Yes
10 (43.5)
No
13 (56.5)
Qualified for criterion (2)
Yes
10 (43.5)
No
13 (56.5)
Qualified for criterion (3)
Yes
15 (65.2)
No
8 (34.8)
Qualified for criterion (4)
Yes
1 (4.3)
No
22 (95.7)
Ulceration of primary
Yes
8 (34.8)
No
12 (52.2)
Unknown
3 (13.0)
Primary site
Ant trunk
6 (26.1)
H/N
3 (13.0)
Pos trunk
4 (17.4)
Upper ext
4 (17.4)
Unknown
6 (26.1)
Primary tumor thickness
Unknown
2 (8.7)
Breslow ≤.75 Clark II
8 (34.8)
Breslow .76–1.5 Clark III
5 (21.7)
Breslow 1.51–4.0 Clark IV
7 (30.4)
Breslow >4.0 Clark V or satellite
1 (4.3)
Nodal site
Axilla
16 (69.6)
Groin
4 (17.4)
Neck
3 (13.0)
Number of positive nodes
Missing
1 (4.3)
0–3
13 (56.5)
4–10
4 (17.4)
>10
5 (21.7)
Nodal involvement
Missing
1 (4.3)
No regional LN
1 (4.3)
1 regional station, node(s) mobile and diameter 3 cm
